Cell Therapeutics (CTIC) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cell Therapeutics (CTIC)

CTIC 9.090

0.0%

Jun 26 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Sam Citron who wrote (643)	3/31/2005 5:21:31 PM
From: Mao II	of 946

The psychology is predictable here. Prior to the less than thrilling ST3 results, the posters on the interesting Yahoo board saw the three Stellar trials as three opportunities. ST3 was generally seen as tough, but ST2 and 4 provided additional chances to show superiority. Now, however, the ST3 results -- which we do not know in any detail -- are seen as the death knell for Xyotax and a clear indicator that 2 and 4 will also go down the tubes. The extremes are clearly marked here. I have to say that Im feeling fairly clueless -- about the possibilities of FDA allowing the NI amendment for ST2 and about the overall prospects. M2

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next